ASH 2018 | RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML
Richard Thomas Maziarz, MD, of the Knight Cancer Institute, Oregon Health & Science University, Portland, OR, discusses the Phase II randomized, open-label RADIUS trial (NCT01883362) investigating whether the addition of midostaurin after ASCT in FLT3-ITD-mutated acute myeloid leukemia (AML) could descrease the risk of relapse. Prof. Maziarz presents the promising results of this study, which met both its primary and secondary endpoints. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up